Bone loss in chronic kidney disease

Kuo Cheng Lu, Cai Mei Zheng, Chia Chao Wu, Pauling Chu

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Patients with chronic kidney disease (CKD) often develop "chronic kidney disease-mineral and bone disorder" (CKD-MBD). This systemic CKD-related syndrome is manifested by complex abnormalities in bone and mineral metabolism-including bone lesions referred to as renal osteodystrophy (ROD)-and/or extraskeletal calcification. Disruptions in mineral metabolism and bone microarchitecture occur early in the course of CKD, typically beginning as a high bone turnover rate resulting from secondary hyperparathyroidism (SHPT). The condition worsens with the progressive decline in kidney function, as the high bone turnover leads to reduced bone mineral density (BMD) during the course of chronic renal failure. Patients with SHPT exhibit preferential loss of cortical bone (e.g., the distal radius and the femoral neck), often with preserved or slightly increased cancellous bone (e.g., the lumbar spine). Several factors impact the progression of CKD-MBD. In CKD stages 3 and 4, patients with diabetes have lower cortical bone BMD when compared with non-diabetic patients. Calcium load also has a negative impact on the progression of vascular calcification in dialysis patients with adynamic bone disease. Low bone volume is associated with increased coronary calcifications in patients on dialysis, with the degree of risk dependent on the patient's age and dialysis duration. Regular treatments with heparin or anti-platelet drugs also impact BMD in hemodialysis (HD) patients. Low BMD is a major risk factor for hip fracture, and this risk is exacerbated in patients undergoing peritoneal dialysis (PD), who show a significant reduction in cortical BMD. Following kidney transplantation, the greatest rates of bone loss and increased fracture rates are observed in the first 6-18 months, caused by both pre-transplantation bone disease and immunosuppressive therapy. Various medical treatments for SHPT can improve bone mass. Patients with refractory SHPT may require a parathyroidectomy (PTX), which provides marked, sustained improvements in BMD. Markers of bone turnover can predict how PTX will change BMD. Renal osteodystrophy can't be assessed by BMD measurements alone; the gold standard for ROD diagnosis is based on histomorphological changes revealed by bone biopsy. However, because of technical difficulties and a lack of testing facilities, it is often more convenient to use several serum bone markers to measure changes in bone turnover. The combined use of BMD and marker measurements may be a valuable approach in clinical practice.

Original languageEnglish
Title of host publicationBone Loss: Risk Factors, Detection and Prevention
PublisherNova Science Publishers, Inc.
Pages1-32
Number of pages32
ISBN (Print)9781624171697
Publication statusPublished - Dec 2012

Fingerprint

Chronic Renal Insufficiency
Bone Density
Bone and Bones
Chronic Kidney Disease-Mineral and Bone Disorder
Secondary Hyperparathyroidism
Bone Remodeling
Dialysis
Bone Diseases
Minerals
Vascular Calcification
Parathyroidectomy
Femur Neck
Hip Fractures
Peritoneal Dialysis
Immunosuppressive Agents
Kidney Transplantation
Chronic Kidney Failure
Renal Dialysis
Heparin
Spine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lu, K. C., Zheng, C. M., Wu, C. C., & Chu, P. (2012). Bone loss in chronic kidney disease. In Bone Loss: Risk Factors, Detection and Prevention (pp. 1-32). Nova Science Publishers, Inc..

Bone loss in chronic kidney disease. / Lu, Kuo Cheng; Zheng, Cai Mei; Wu, Chia Chao; Chu, Pauling.

Bone Loss: Risk Factors, Detection and Prevention. Nova Science Publishers, Inc., 2012. p. 1-32.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lu, KC, Zheng, CM, Wu, CC & Chu, P 2012, Bone loss in chronic kidney disease. in Bone Loss: Risk Factors, Detection and Prevention. Nova Science Publishers, Inc., pp. 1-32.
Lu KC, Zheng CM, Wu CC, Chu P. Bone loss in chronic kidney disease. In Bone Loss: Risk Factors, Detection and Prevention. Nova Science Publishers, Inc. 2012. p. 1-32
Lu, Kuo Cheng ; Zheng, Cai Mei ; Wu, Chia Chao ; Chu, Pauling. / Bone loss in chronic kidney disease. Bone Loss: Risk Factors, Detection and Prevention. Nova Science Publishers, Inc., 2012. pp. 1-32
@inbook{be72291dd3fa47d1968f955ee036d8df,
title = "Bone loss in chronic kidney disease",
abstract = "Patients with chronic kidney disease (CKD) often develop {"}chronic kidney disease-mineral and bone disorder{"} (CKD-MBD). This systemic CKD-related syndrome is manifested by complex abnormalities in bone and mineral metabolism-including bone lesions referred to as renal osteodystrophy (ROD)-and/or extraskeletal calcification. Disruptions in mineral metabolism and bone microarchitecture occur early in the course of CKD, typically beginning as a high bone turnover rate resulting from secondary hyperparathyroidism (SHPT). The condition worsens with the progressive decline in kidney function, as the high bone turnover leads to reduced bone mineral density (BMD) during the course of chronic renal failure. Patients with SHPT exhibit preferential loss of cortical bone (e.g., the distal radius and the femoral neck), often with preserved or slightly increased cancellous bone (e.g., the lumbar spine). Several factors impact the progression of CKD-MBD. In CKD stages 3 and 4, patients with diabetes have lower cortical bone BMD when compared with non-diabetic patients. Calcium load also has a negative impact on the progression of vascular calcification in dialysis patients with adynamic bone disease. Low bone volume is associated with increased coronary calcifications in patients on dialysis, with the degree of risk dependent on the patient's age and dialysis duration. Regular treatments with heparin or anti-platelet drugs also impact BMD in hemodialysis (HD) patients. Low BMD is a major risk factor for hip fracture, and this risk is exacerbated in patients undergoing peritoneal dialysis (PD), who show a significant reduction in cortical BMD. Following kidney transplantation, the greatest rates of bone loss and increased fracture rates are observed in the first 6-18 months, caused by both pre-transplantation bone disease and immunosuppressive therapy. Various medical treatments for SHPT can improve bone mass. Patients with refractory SHPT may require a parathyroidectomy (PTX), which provides marked, sustained improvements in BMD. Markers of bone turnover can predict how PTX will change BMD. Renal osteodystrophy can't be assessed by BMD measurements alone; the gold standard for ROD diagnosis is based on histomorphological changes revealed by bone biopsy. However, because of technical difficulties and a lack of testing facilities, it is often more convenient to use several serum bone markers to measure changes in bone turnover. The combined use of BMD and marker measurements may be a valuable approach in clinical practice.",
author = "Lu, {Kuo Cheng} and Zheng, {Cai Mei} and Wu, {Chia Chao} and Pauling Chu",
year = "2012",
month = "12",
language = "English",
isbn = "9781624171697",
pages = "1--32",
booktitle = "Bone Loss: Risk Factors, Detection and Prevention",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Bone loss in chronic kidney disease

AU - Lu, Kuo Cheng

AU - Zheng, Cai Mei

AU - Wu, Chia Chao

AU - Chu, Pauling

PY - 2012/12

Y1 - 2012/12

N2 - Patients with chronic kidney disease (CKD) often develop "chronic kidney disease-mineral and bone disorder" (CKD-MBD). This systemic CKD-related syndrome is manifested by complex abnormalities in bone and mineral metabolism-including bone lesions referred to as renal osteodystrophy (ROD)-and/or extraskeletal calcification. Disruptions in mineral metabolism and bone microarchitecture occur early in the course of CKD, typically beginning as a high bone turnover rate resulting from secondary hyperparathyroidism (SHPT). The condition worsens with the progressive decline in kidney function, as the high bone turnover leads to reduced bone mineral density (BMD) during the course of chronic renal failure. Patients with SHPT exhibit preferential loss of cortical bone (e.g., the distal radius and the femoral neck), often with preserved or slightly increased cancellous bone (e.g., the lumbar spine). Several factors impact the progression of CKD-MBD. In CKD stages 3 and 4, patients with diabetes have lower cortical bone BMD when compared with non-diabetic patients. Calcium load also has a negative impact on the progression of vascular calcification in dialysis patients with adynamic bone disease. Low bone volume is associated with increased coronary calcifications in patients on dialysis, with the degree of risk dependent on the patient's age and dialysis duration. Regular treatments with heparin or anti-platelet drugs also impact BMD in hemodialysis (HD) patients. Low BMD is a major risk factor for hip fracture, and this risk is exacerbated in patients undergoing peritoneal dialysis (PD), who show a significant reduction in cortical BMD. Following kidney transplantation, the greatest rates of bone loss and increased fracture rates are observed in the first 6-18 months, caused by both pre-transplantation bone disease and immunosuppressive therapy. Various medical treatments for SHPT can improve bone mass. Patients with refractory SHPT may require a parathyroidectomy (PTX), which provides marked, sustained improvements in BMD. Markers of bone turnover can predict how PTX will change BMD. Renal osteodystrophy can't be assessed by BMD measurements alone; the gold standard for ROD diagnosis is based on histomorphological changes revealed by bone biopsy. However, because of technical difficulties and a lack of testing facilities, it is often more convenient to use several serum bone markers to measure changes in bone turnover. The combined use of BMD and marker measurements may be a valuable approach in clinical practice.

AB - Patients with chronic kidney disease (CKD) often develop "chronic kidney disease-mineral and bone disorder" (CKD-MBD). This systemic CKD-related syndrome is manifested by complex abnormalities in bone and mineral metabolism-including bone lesions referred to as renal osteodystrophy (ROD)-and/or extraskeletal calcification. Disruptions in mineral metabolism and bone microarchitecture occur early in the course of CKD, typically beginning as a high bone turnover rate resulting from secondary hyperparathyroidism (SHPT). The condition worsens with the progressive decline in kidney function, as the high bone turnover leads to reduced bone mineral density (BMD) during the course of chronic renal failure. Patients with SHPT exhibit preferential loss of cortical bone (e.g., the distal radius and the femoral neck), often with preserved or slightly increased cancellous bone (e.g., the lumbar spine). Several factors impact the progression of CKD-MBD. In CKD stages 3 and 4, patients with diabetes have lower cortical bone BMD when compared with non-diabetic patients. Calcium load also has a negative impact on the progression of vascular calcification in dialysis patients with adynamic bone disease. Low bone volume is associated with increased coronary calcifications in patients on dialysis, with the degree of risk dependent on the patient's age and dialysis duration. Regular treatments with heparin or anti-platelet drugs also impact BMD in hemodialysis (HD) patients. Low BMD is a major risk factor for hip fracture, and this risk is exacerbated in patients undergoing peritoneal dialysis (PD), who show a significant reduction in cortical BMD. Following kidney transplantation, the greatest rates of bone loss and increased fracture rates are observed in the first 6-18 months, caused by both pre-transplantation bone disease and immunosuppressive therapy. Various medical treatments for SHPT can improve bone mass. Patients with refractory SHPT may require a parathyroidectomy (PTX), which provides marked, sustained improvements in BMD. Markers of bone turnover can predict how PTX will change BMD. Renal osteodystrophy can't be assessed by BMD measurements alone; the gold standard for ROD diagnosis is based on histomorphological changes revealed by bone biopsy. However, because of technical difficulties and a lack of testing facilities, it is often more convenient to use several serum bone markers to measure changes in bone turnover. The combined use of BMD and marker measurements may be a valuable approach in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84892002290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892002290&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84892002290

SN - 9781624171697

SP - 1

EP - 32

BT - Bone Loss: Risk Factors, Detection and Prevention

PB - Nova Science Publishers, Inc.

ER -